Lineage Cell Therapeutics projects cash sufficiency into late 2028 and targets in vivo data for its COR1 program by year-end.
Lineage Cell Therapeutics (LCTX) announced it has secured cash reserves to fund operations through Q3 2028. The extension follows progress in its OpRegen program, which has enabled internal pipeline expansion for cell therapy assets.
Management highlighted milestones from Q2 2026, emphasizing a shift toward a more internally controlled development strategy. The company now aims to release in vivo data for its COR1 program by the end of the year.
No immediate market reaction was disclosed in the earnings call insights.